[go: up one dir, main page]

WO2012112690A3 - Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains - Google Patents

Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains Download PDF

Info

Publication number
WO2012112690A3
WO2012112690A3 PCT/US2012/025261 US2012025261W WO2012112690A3 WO 2012112690 A3 WO2012112690 A3 WO 2012112690A3 US 2012025261 W US2012025261 W US 2012025261W WO 2012112690 A3 WO2012112690 A3 WO 2012112690A3
Authority
WO
WIPO (PCT)
Prior art keywords
targeting
binding domains
diagnostic agents
therapeutic drugs
collagen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/025261
Other languages
French (fr)
Other versions
WO2012112690A2 (en
Inventor
Marcel E. Nimni
Bo Han
Peter BOASBERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FABIUS BIOTECHNOLOGY
Original Assignee
FABIUS BIOTECHNOLOGY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FABIUS BIOTECHNOLOGY filed Critical FABIUS BIOTECHNOLOGY
Publication of WO2012112690A2 publication Critical patent/WO2012112690A2/en
Anticipated expiration legal-status Critical
Publication of WO2012112690A3 publication Critical patent/WO2012112690A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A targeting composition comprising: (1) a therapeutic agent; (2) an intermediate release linker bound to the therapeutic agent; and (3) a targeting moiety bound to the intermediate release linker, the targeting moiety for binding the targeting composition to native collagen fibers, provides an improved means of targeting therapeutic agents to cells, particularly malignant cells. The therapeutic agents can be, but are not limited to, anti-neoplastic agents or anti-inflammatory agents. The peptide motif can be a motif derived from the sequence present in von Willebrand's factor. The invention also encompasses pharmaceutical compositions and methods of treatment, as well as diagnostic compositions.
PCT/US2012/025261 2011-02-16 2012-02-15 Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains Ceased WO2012112690A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161443346P 2011-02-16 2011-02-16
US61/443,346 2011-02-16

Publications (2)

Publication Number Publication Date
WO2012112690A2 WO2012112690A2 (en) 2012-08-23
WO2012112690A3 true WO2012112690A3 (en) 2014-04-24

Family

ID=46673155

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/025261 Ceased WO2012112690A2 (en) 2011-02-16 2012-02-15 Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains

Country Status (1)

Country Link
WO (1) WO2012112690A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
WO2012021512A2 (en) 2010-08-10 2012-02-16 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US20140271814A1 (en) * 2013-03-14 2014-09-18 Shiva Andrali Cell binding peptide drug delivery system and compound for treating cancer and tumors
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
LT3107563T (en) 2014-02-21 2021-07-12 Ecole Polytechnique Fédérale De Lausanne (Epfl) Epfl-Tto Glycotargeting therapeutics
CN106188306B (en) * 2015-05-04 2020-07-24 北京同建再生医学技术有限公司 Therapeutic recombinant antibody, coding gene and application thereof
US11129798B2 (en) * 2016-08-19 2021-09-28 Aron H. Blaesi Fibrous dosage form
CN107699562B (en) * 2016-08-08 2021-07-09 西南医科大学附属中医医院 Magnetic capture technology of hepatitis B covalently closed circular DNA
CN106841192B (en) * 2017-04-18 2019-05-03 乐凯（沈阳）科技产业有限责任公司 A kind of diazepine structure directing agent detection carbaldehyde Method and its application
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
CN112236445A (en) * 2017-12-14 2021-01-15 芝加哥大学 Treatment of fibrosis with genetically engineered macrophages
BR112020013656A2 (en) 2018-01-05 2020-12-01 Platelet Biogenesis, Inc. compositions and methods for producing megakaryocytes
CN108130355A (en) * 2018-02-11 2018-06-08 华南理工大学 A kind of collagen polypeptide rich in glycine and formaldehyde scavenger prepared therefrom
US12365714B2 (en) 2018-03-05 2025-07-22 The University Of Chicago Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines
US12188065B2 (en) 2018-03-29 2025-01-07 The University Of Liverpool Peptides and conjugates
EA202092723A1 (en) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго COMPOSITIONS AND METHODS CONCERNING IMMUNE TOLERANCE
JP2021529770A (en) 2018-06-29 2021-11-04 プレートレット バイオジェネシス， インコーポレイテッド Compositions for drug delivery and how to use them
HUE062848T2 (en) 2018-09-14 2023-12-28 Enlitisa Shanghai Pharmaceutical Co Ltd Conjugates of montelukast and peptides
WO2020068665A1 (en) * 2018-09-27 2020-04-02 Fabius Biotechnology Use of collagen binding domains to deliver products to skin
BR112021004383A2 (en) * 2018-09-28 2021-08-03 Massachusetts Institute Of Technology immunomodulatory fusion protein, pharmaceutical composition, nucleic acid, expression vector, transformed cell, method for producing an immunomodulatory fusion protein, method for activating, enhancing or promoting a response by an immune cell in a subject, method for inhibiting, reducing or suppressing a response by an immune cell in a subject, method of reducing or inhibiting tumor growth, method of treating cancer in a subject, kit, use of an immunomodulatory fusion protein, and method of reducing or inhibiting tumor growth or treat cancer in a subject
WO2020108753A1 (en) * 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
CN113710229A (en) * 2019-02-25 2021-11-26 芝加哥大学 Methods and compositions for treating inflammatory and autoimmune disorders with ECM affinity peptides linked to anti-inflammatory agents
EP3976111A4 (en) * 2019-06-03 2023-07-05 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING COLLAGEN-BINDING DRUG VECTORS
CN110734470B (en) * 2019-11-18 2021-04-16 浙江省农业科学院 Silkworm pupa protein peptide HPP for reducing blood fat and application thereof
US20230348378A1 (en) * 2020-08-20 2023-11-02 Oregon Health & Science University Small molecule albumin binders
WO2022225906A2 (en) * 2021-04-20 2022-10-27 The Board Of Trustees Of The Leland Stanford Junior University Polymer liposome hydrogel
EP4536697A1 (en) * 2022-06-06 2025-04-16 Collagen Matrix, Inc. Collagen-impregnated devices and methods for treatment of cancer
CN116059322A (en) * 2023-02-15 2023-05-05 中孚生物医药科技发展(辽宁)有限公司 Oral preparation for treating and preventing tumor and preparation method thereof
CN118878617A (en) * 2024-07-09 2024-11-01 皖南医学院第一附属医院（皖南医学院弋矶山医院） A method for synthesizing a polypeptide anti-inflammatory hydrogel gelling factor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118551A1 (en) * 1997-04-10 2003-06-26 University Of Southern California Modified viral surface proteins for binding to extracellular matrix components
US20030133972A1 (en) * 2000-10-11 2003-07-17 Targesome, Inc. Targeted multivalent macromolecules
US20070224620A1 (en) * 2006-02-08 2007-09-27 Promega Corporation Compositions and methods for capturing and analyzing cross-linked biomolecules
US20080069774A1 (en) * 2005-11-17 2008-03-20 Lance Liotta Proteomic antisense molecular shield and targeting

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118551A1 (en) * 1997-04-10 2003-06-26 University Of Southern California Modified viral surface proteins for binding to extracellular matrix components
US20030133972A1 (en) * 2000-10-11 2003-07-17 Targesome, Inc. Targeted multivalent macromolecules
US20080069774A1 (en) * 2005-11-17 2008-03-20 Lance Liotta Proteomic antisense molecular shield and targeting
US20070224620A1 (en) * 2006-02-08 2007-09-27 Promega Corporation Compositions and methods for capturing and analyzing cross-linked biomolecules

Also Published As

Publication number Publication date
WO2012112690A2 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
WO2012112690A3 (en) Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
MX2012008603A (en) Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity.
UA117072C2 (en) CD3-Binding Molecule Able to Bind to CD3 HUMAN AND NON-HUMAN CD3
WO2008063291A3 (en) Polypeptide ligands for targeting cartilage and methods of use thereof
UA107921C2 (en) Variants of polypeptide of receptor ivr activin and their use
UA117216C2 (en) TUMOR ASSOCIATED PEPTIDE AND ITS APPLICATION
MX369679B (en) ANTIBODY DRUG CONJUGATES (ADC) BINDING TO PROTEINS 191P4D12.
EP3466416A3 (en) A binding moiety-drug conjugate comprising a hsp90 binding moiety and a cytotoxic effector moiety
MY162564A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
PE20110435A1 (en) ANTAGONIST COMPOSITIONS OF PD-1
WO2012090150A3 (en) New cell-penetrating peptides and uses thereof
EA201390642A1 (en) CYTOTOXIC AGENTS CONTAINING NEW DERIVATIVES OF ANZAMITOCINE
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
BRPI1006115A8 (en) "APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES".
GB201001602D0 (en) Oligopeptidic compounds and uses therof
EA201490822A1 (en) MODIFIED ACTIVIN RECEPTOR POLYPEPTIDES AND THEIR APPLICATION
UA102867C2 (en) Anti cxcr4 antibodies and their use for the treatment of cancer
WO2012054500A3 (en) Compositions for drug administration
IN2012DN02981A (en)
WO2012177653A3 (en) Targeting the neuromuscular junction for treatment
MX2009002787A (en) Compositions and methods to prevent cancer with cupredoxins.
WO2008108808A3 (en) Complexes derived from heterohybrid cells and uses thereof
EA201491259A1 (en) COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF BCL2 WITH BOND PARTNERS
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12746741

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12746741

Country of ref document: EP

Kind code of ref document: A2